Question to the Department of Health and Social Care:

To ask His Majesty's Government what information they have on countries currently implementing immunisation programmes for infant respiratory syncytial virus with regard to (1) acceptance and uptake, and (2) hospitalisations.

In the United States, as of 31 January 2024, maternal immunisation was 17.9%. By February 2024, 43% of infants under eight months old had received a dose of nirsevimab.

In Galicia, Spain, 92.9% of 5,357 infants born from 25 September 2023 to 4 February 2024 had nirsevimab, as well as 79.7% of 5,823 infants included in a catch-up programme. The peak of the hospitalisation rate in infants under six months old was 102 per 100,000 in 2023/24, during the week starting 27 November 2023. This is compared to a median of 776 for 2017/18, 2018/19 and 2019/20, peaking during the first week of the January.

In Luxembourg, 84% of 1524 infants born in hospital between early October and mid-December 2023 received nirsevimab. Luxembourg observed a decrease in hospitalisation in infants under six months old of 69%, between the 2022/23 and 2023/24 respiratory syncytial virus seasons.